We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00742079
Recruitment Status : Completed
First Posted : August 27, 2008
Results First Posted : September 5, 2014
Last Update Posted : December 19, 2017
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Donald C. Goff, MD, Massachusetts General Hospital

August 25, 2008
August 27, 2008
August 11, 2014
September 5, 2014
December 19, 2017
September 2006
July 2010   (Final data collection date for primary outcome measure)
Change in Alternative Beliefs Assessment [ Time Frame: Baseline to Week 2 ]
Number of alternative beliefs generated on the Alternative Beliefs Assessment. This assessment used nine vignettes describing social interactions: three of neutral content, three negatively-valanced, and three tailored to the patient's specific delusions. Participants were asked to generate as many explanations (alternative beliefs) as they could for each scenario, and the number of explanations produced in response to each item was recorded. Scores could range from 0 to as many explanations a person could produce (no maximum value). The total score was calculated by adding all alternative beliefs generated from each vignette. A higher number of alternative beliefs generated reflects a greater degree of cognitive flexibility.
Total delusion score as rated by the Scale for the Assessment of Positive Symptoms (SAPS) [ Time Frame: Measured at Weeks 1, 2, and 3 ]
Complete list of historical versions of study NCT00742079 on ClinicalTrials.gov Archive Site
  • Change in Psychotic Rating Scales (PSYRATS) Delusion Score [ Time Frame: Baseline to Week 2 ]
    The Delusions subscale is a 6 item clinician administered scale, with Likert items 0-4 and range is 0-24. Higher scores represent worse outcomes
  • Change in Beck Cognitive Insight Scale (BCIS) [ Time Frame: Baseline to Week 2 ]

    The BCIS is a 15-item self-report scale with Likert items 0-3. It consists of a composite score, where higher scores represent better outcomes, and there are 2 subscales: 1) Self-Reflectiveness (higher scores represent better outcomes) and 2) Self-Certainty (higher scores represent worse outcomes). The total score for each scale is the sum of the item scores that comprise it (see below). The BCIS composite index is calculated as self-reflectiveness minus self-certainty.

    Step 1. Score every item on the BCIS from "0" to "3" according to the following rule:

    "Do Not Agree at All" = 0, "Agree Slightly" = 1, "Agree a Lot" = 2, "Agree Completely" = 3 Step 2. Calculate self-reflectiveness subscale: sum items 1, 3, 4, 5, 6, 8, 12, 14, and 15.

    Step 3. Calculate self-certainty subscale: sum items 2, 7, 9, 10, 11, and 13. Step 4. Calculate BCIS composite index: self-reflectiveness minus self-certainty.

  • Change in Bead Task Score Measuring Probabilistic Reasoning [ Time Frame: Baseline to Week 2 ]
    The Bead task is a reasoning task, where the number of beads guessed is the numeric value represented in the data. The lower end range is 1, and there is no upper range limit. Higher scores represent better outcomes.
  • Change in the Maudsley Assessment of Delusions Scale [ Time Frame: Baseline to Week 2 ]
    This scale is a one-question item added on to the Bead Task. The one item asks for a certainty rating, from 1-3. Higher scores represent better outcomes.
  • Cognitive flexibility, as defined by number of alternative explanations generated in response to neutral, negative, and delusion-specific stimuli [ Time Frame: Measured at Weeks 1, 2, and 3 ]
  • Predictors of Response to D-cycloserine Facilitation of CBT for Delusions in Baseline Characteristics [ Time Frame: Measured at baseline ]
  • Psychotic Rating Scales (PSYRATS) [ Time Frame: Measured at Weeks 1, 2, and 3 ]
  • Beck Cognitive Insight Scale (BCIS) [ Time Frame: Measured at Weeks 1, 2, and 3 ]
  • Bead Task Measuring Probabilistic Reasoning [ Time Frame: Measured at Weeks 1, 2, and 3 ]
  • Affective Salience Task [ Time Frame: Measured at Weeks 1, 2, and 3 ]
  • Select Items From the Maudsley Assessment of Delusions Scale [ Time Frame: Measured at Weeks 1, 2, and 3 ]
Not Provided
Not Provided
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia
This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment.

Schizophrenia is a debilitating chronic condition that affects approximately 1 % of Americans, who experience symptoms such as hallucinations, delusions, and disorders of thought and movement. These symptoms are described as positive symptoms, because they are experienced in addition to what healthy individuals experience. Negative symptoms, which are reductions in normal functioning, and cognitive deficits, which are problems in thinking, also plague people with schizophrenia. The negative symptoms and cognitive deficits associated with schizophrenia are produced in otherwise healthy people by neurotransmitters inhibiting the glutamatergic N-methyl-d-aspartate NMDA receptors in the brain. This inhibition of NMDA receptors also causes intensification of psychotic symptoms in otherwise stabilized schizophrenic patients. The drug D-cycloserine partially excites NMDA receptors, and it has been used to help patients with anxiety disorders to overcome phobias while they are receiving cognitive behavioral therapy. This study will examine whether D-cycloserine can increase the cognitive flexibility of someone undergoing CBT and thereby enhance the therapy's ability to reduce a patient's belief in paranoid delusions, preoccupation with delusions, and related distress.

All participants will be screened to ensure proper diagnosis of schizophrenia without other conditions. Those who pass will be randomly assigned to receive either D-cycloserine first or a placebo pill first. One week after the screening, participants in the D-cycloserine group will be given the drug before a 1-hour session of simulated CBT treatment. Those in the placebo condition will receive a placebo pill before an identical session. Two weeks after the screening, both groups will be called back for another session of CBT, but the pills they receive will be switched. Those who received D-cycloserine the first week will receive placebo, and those who received placebo will receive D-cycloserine. The CBT sessions will attempt to increase cognitive flexibility in patients by asking them to provide alternate explanations for common situations. At screening, at the start of visits on the first and second weeks, and at a follow-up visit on the third week, participants will undergo a series of assessments, including interviews, computerized tests, and self-report measures. Belief in, preoccupation with, and distress caused by delusions, as well as degree of cognitive flexibility, will be assessed.

Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: D-cycloserine
    Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
    Other Name: Seromycin
  • Behavioral: Cognitive Behavioral Therapy
    One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
    Other Name: CBT
  • Experimental: 1 D-cycloserine, placebo
    Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
    • Drug: D-cycloserine
    • Behavioral: Cognitive Behavioral Therapy
  • Experimental: 2 Placebo, D-cycloserine
    Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
    • Drug: D-cycloserine
    • Behavioral: Cognitive Behavioral Therapy
Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res. 2011 Sep;131(1-3):69-74. doi: 10.1016/j.schres.2011.05.029. Epub 2011 Jun 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2010
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets DSM-IV criteria for schizophrenia, schizoaffective disorder, or schizophrenia, paranoid subtype, based on chart review, Structured Clinical Interview for DSM-IV, and consultation with the patient's clinicians
  • Medicated with an antipsychotic agent other than clozapine at a stable dose for at least 6 weeks
  • Scores at least 3, or "moderate," on the Scale for the Assessment of Positive Symptoms global delusion rating
  • Paranoid or referential delusional content
  • Never engaged in formal CBT psychotherapy in the past

Exclusion Criteria:

  • Diagnosis of a comorbid Axis I disorder other than schizophrenia
  • Active substance abuse or dependence within 6 months
  • Significant suicidal ideation within 6 weeks
  • Pregnant or nursing
  • Unstable medical disorder
  • impaired renal clearance (creatinine <60mg/dL/min)
  • Suffering from dementia
  • Suffering from seizure disorder
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
P50MH060450( U.S. NIH Grant/Contract )
2P50MH060450-07A1 ( U.S. NIH Grant/Contract )
DATR A3-NSC ( Other Grant/Funding Number: National Institute of Mental Health )
Not Provided
Not Provided
Donald C. Goff, MD, Massachusetts General Hospital
Massachusetts General Hospital
National Institute of Mental Health (NIMH)
Principal Investigator: Donald C. Goff, MD Massachusetts General Hospital
Massachusetts General Hospital
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP